安领科生物成立于2023年,是一家聚焦肿瘤及免疫领域的临床阶段生物技术公司,致力于差异化 ADC 及多特异性抗体的研发创新。基于创新平台技术与卓越研发效率的双重驱动,公司已迅速将两款 ADC 候选药物推至全球 I 期临床阶段。
安领科生物的使命是通过 ADC 与多特异性抗体的持续创新,惠及全球病患。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows